IDEXX Laboratories raised its 2026 earnings outlook to $14.69-$14.94 per share from $14.45-$14.90 after second-quarter earnings of $4.27 per share beat the Zacks Consensus Estimate by 8.1%. Revenues rose 10% to $1.22 billion, with Companion Animal Group Diagnostics recurring revenues up 10% organically. Operating margin expanded 140 basis points to 35%, and gross margin improved 140 basis points to 64%. The company updated 2026 revenue guidance to $4.70-$4.75 billion from $4.68-$4.76 billion, with the midpoint rising $5 million despite a projected $15-million currency headwind. U.S. same-store clinical visits declined an estimated 1.3% in the second quarter, while wellness visits fell 3.4%.
IDEXX Laboratories IncRaises 2026 EPS outlook and beats Q2 estimates with strong revenue growth and margin expansion
Abbott Laboratories
Laboratory Corporation of America Holdings